

# Warrants of series TO6 were subscribed to approximately 94 percent and Lumito receives approximately SEK 12.6 million

Lumito AB (publ) ("Lumito" or the "Company") today announces the outcome of the exercise of warrants of series TO6, which were issued in connection to an issue and loan financing during the fourth quarter of 2023. In total, 32,206,770 warrants were exercised, corresponding to approximately 94 percent of the total number of outstanding warrants, for subscription of 32,206,770 shares at a subscription price of SEK 0.39 per share. Through the exercise of the warrants Lumito will receive approximately SEK 12.6 million before issuing costs.

## Background

The exercise period for the warrants of series TO6 ran during the period from and including November 4, 2024, to and including November 15, 2024. The subscription price per share upon exercise of the warrants of series TO6 was set at 0.39 SEK.

"I am honored and grateful for the great interest shown by our shareholders. Being a new CEO, this truly means a lot. We are in an exciting phase where perseverance is important. We have a great product that meets unmet needs. We will with continued high focus interact and collaborate with users and potential customers to attract key opinion leaders, and to start generating revenue to Lumito", Sanna Wallenborg, Lumito CEO.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.

## Shares, share capital and dilution

Through the exercise of the warrants, the number of shares in Lumito increases by 32,206,770 shares, from 233,691,423 shares to a total of 265,898,193 shares. The share capital will increase by SEK 805,169.25 from SEK 5,842,285.58 to SEK 6,647,454.83. For existing shareholders who did not exercise any warrants, the dilution amounts to approximately 12.1 percent of the number of shares and votes in the Company.

## Advisers

Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor to Lumito in connection with the exercise of the warrants of series TO6.

## For further information, please contact:

---

Sanna Wallenborg, CEO Lumito

E-mail: [sw@lumito.se](mailto:sw@lumito.se)

Ph: +4670-870 01 68

*This information is information that Lumito is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-18 19:55 CET.*

## About Lumito

---

**Lumito** specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. [www.lumito.se/en](http://www.lumito.se/en)

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

## Attachments

[Warrants of series TO6 were subscribed to approximately 94 percent and Lumito receives approximately SEK 12.6 million](#)